127 related articles for article (PubMed ID: 9492224)
21. The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.
Baettig U; Brown L; Brundish D; Dell C; Furzer A; Garman S; Janus D; Kane PD; Smith G; Walker CV; Cockcroft X; Ambler J; Mitchelson A; Talbot MD; Tweed M; Wills N
Bioorg Med Chem Lett; 2000 Jul; 10(14):1563-6. PubMed ID: 10915051
[TBL] [Abstract][Full Text] [Related]
22. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
23. The thrombin inhibitor argatroban does not influence the endothelium-dependent relaxant and contractile responses of isolated rabbit carotid arteries.
Schrödter HM; Glusa E
Exp Toxicol Pathol; 2003 Jun; 54(5-6):499-504. PubMed ID: 12877364
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and anti-thrombotic evaluation of some novel fluorinated thrombin inhibitor derivatives.
Chen H; Ren Y
Arch Pharm (Weinheim); 2015 Jun; 348(6):408-20. PubMed ID: 25881141
[TBL] [Abstract][Full Text] [Related]
25. Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Tamao Y; Kikumoto R
Semin Thromb Hemost; 1997; 23(6):523-30. PubMed ID: 9469624
[TBL] [Abstract][Full Text] [Related]
26. Enzyme-controlling medicines: introduction.
Okamoto S; Hijikata-Okunomiya A; Wanaka K; Okada Y; Okamoto U
Semin Thromb Hemost; 1997; 23(6):493-501. PubMed ID: 9469621
[TBL] [Abstract][Full Text] [Related]
27. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
[TBL] [Abstract][Full Text] [Related]
28. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
30. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Asanuma K; Wakabayashi H; Okamoto T; Asanuma Y; Akita N; Yoshikawa T; Hayashi T; Matsumine A; Uchida A; Sudo A
Breast Cancer; 2013 Jul; 20(3):241-6. PubMed ID: 22359194
[TBL] [Abstract][Full Text] [Related]
31. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
Escolar G; Bozzo J; Maragall S
Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
[TBL] [Abstract][Full Text] [Related]
32. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.
Li N; He S; Blombäck M; Hjemdahl P
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):407-13. PubMed ID: 17138937
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of various thrombin inhibitors on shear-induced platelet function and dynamic coagulation.
Taka T; Konishi Y; Slon-Usakiewicz J; Medvedkin V; Tsuda Y; Okada Y; Seki J; Yamamoto J
Eur J Pharmacol; 2000 Oct; 406(2):181-9. PubMed ID: 11020480
[TBL] [Abstract][Full Text] [Related]
34. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
[TBL] [Abstract][Full Text] [Related]
35. Influences of argatroban on five fibrinogen assays.
Zhang L; Yang J; Zheng X; Fan Q; Zhang Z
Int J Lab Hematol; 2017 Dec; 39(6):641-644. PubMed ID: 28766891
[TBL] [Abstract][Full Text] [Related]
36. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Matsuo T; Koide M; Kario K
Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
[TBL] [Abstract][Full Text] [Related]
37. Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Aliter KF; Al-Horani RA
Cardiovasc Drugs Ther; 2021 Apr; 35(2):195-203. PubMed ID: 32870433
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of argatroban.
Jeske WP; Fareed J; Hoppensteadt DA; Lewis B; Walenga JM
Expert Rev Hematol; 2010 Oct; 3(5):527-39. PubMed ID: 21083469
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
